Home » Stocks » Johnson & Johnson

Johnson & Johnson (JNJ)

Stock Price: $140.97 USD 0.59 (0.42%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 371.40B
Revenue (ttm) 82.73B
Net Income (ttm) 17.17B
Shares Out 2.64B
EPS (ttm) 6.41
PE Ratio 21.99
Forward PE 18.45
Dividend $4.04
Dividend Yield 2.87%

Stock Quote

Trading Day Jul 2, 2020
Last Price $140.97
Previous Close $140.38
Change ($) 0.59
Change (%) 0.42%
Day's Open 141.25
Day's Range 140.33 - 141.84
Day's Volume 5,152,238
52-Week Range 109.16 - 157.00

More Stats

Market Cap 371.40B
Enterprise Value 380.96B
Earnings Date (est) Jul 16, 2020
Ex-Dividend Date May 22, 2020
Shares Outstanding 2.64B
Float 2.63B
EPS (basic) 6.51
EPS (diluted) 6.41
FCF / Share 7.50
Dividend $4.04
Dividend Yield 2.87%
Earnings Yield 4.55%
FCF Yield 5.32%
Payout Ratio 58.40%
Shares Short 13.01M
Short Ratio 1.79
Short % of Float 0.49%
Beta 0.70
PE Ratio 21.99
Forward PE 18.45
P/FCF Ratio 18.79
PS Ratio 4.49
PB Ratio 6.14
Revenue 82.73B
Operating Income 21.20B
Net Income 17.17B
Free Cash Flow 19.76B
Net Cash -9.56B
Net Cash / Share -3.63
Gross Margin 66.00%
Operating Margin 25.62%
Profit Margin 20.70%
FCF Margin 23.89%
ROA 8.83%
ROE 28.55%
ROIC 37.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (20)

Buy 11
Overweight 2
Hold 6
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

(16.02% upside)
Current: 140.97
Target: 163.56
*Average 12-month price target from 18 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth0.59%6.71%6.34%2.59%-5.73%4.23%6.08%3.37%5.59%-
Gross Profit54,50354,49051,01150,10148,53851,58548,97045,56644,67042,795
Operating Income19,81419,79818,18020,37117,55620,95918,37715,86915,58416,527
Net Income15,11915,2971,30016,54015,40916,32313,83110,8539,67213,334
Shares Outstanding2,6452,6822,6922,7372,7722,8152,8092,7532,7362,751
Earnings Per Share5.635.610.475.935.485.704.813.863.494.78
EPS Growth0.36%1093.62%-92.07%8.21%-3.86%18.5%24.61%10.6%-26.99%-
Dividend Per Share3.753.543.323.152.952.762.592.402.252.11
Dividend Growth5.93%6.63%5.4%6.78%6.88%6.56%7.92%6.67%6.64%-
Operating Cash Flow23,41622,20121,05618,76719,56918,71017,41415,39614,29816,385
Capital Expenditures-3,498-3,670-3,279-3,226-3,463-3,714-3,595-2,934-2,893-2,384
Free Cash Flow19,91818,53117,77715,54116,10614,99613,81912,46211,40514,001
Cash & Equivalents19,28719,68718,29641,90738,37633,08929,20621,08932,26127,658
Total Debt27,69630,48034,58127,12619,86118,76018,18016,16519,62716,773
Net Cash / Debt-8,409-10,793-16,28514,78118,51514,32911,0264,92412,63410,885
Book Value59,47159,75260,16070,41871,15069,75274,05364,82657,08056,579
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Johnson & Johnson
Country United States
Employees 132,200
CEO Alex Gorsky

Stock Information

Ticker Symbol JNJ
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NYSE: JNJ


Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; sterilization and disinfection products to reduce surgical infection; diabetes care products; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. It has collaboration agreements with Morphic Therapeutic; and Emergent BioSolutions, Inc. The company was founded in 1886 and is based in New Brunswick, New Jersey.